



Attorney Docket No. 5698.220-US  
Jeppesen et al.  
Serial No. 10/076,575 Filed February 8, 2002  
Express Mail Label No. EV 409532886 US

Attorney Docket No.: 5698.220-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jeppesen et al.

Serial No.: 10/076,575

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthom Ngo

For: Substituted Hetero-Polycyclic Compounds as PPAR $\alpha$  and PPAR $\gamma$  Activators (As Amended)

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**

MAR 05 2004

Sir:

I hereby certify that the attached correspondence comprising:

TECH CENTER 1600/2900

1. Amendment/Response
2. Request for Corrected Filing Receipt
3. Copy of Filing Receipt

is being deposited with the United States Postal Service as Express Mail Label No. EV 409532886  
US in an envelope addressed to:


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 4, 2004

Dolly Kapadia

(name of person mailing paper)

*Dolly Kapadia*  
(signature of person mailing paper)



02/05/04 / RECEIPT

Attorney Docket No.: 5698.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 10/076,575

Group Art Unit: 1624

Filed: February 8, 2002

Examiner: Truong, Tamthom Ngo

For: Substituted Hetero-Polycyclic Compounds as PPAR $\alpha$  and PPAR $\gamma$  Activators (As Amended)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED

MAR 05 2004

TECH CENTER 1600/2300

Sir:

Applicants filed the above-captioned application on February 8, 2002.


The filing receipt received by Applicants incorrectly indicates the title as "Substituted hetero-polycyclic compounds as PPAR $\alpha$  and PPAR $\gamma$ ". The correct title should read --Substituted Hetero-Polycyclic Compounds as PPAR $\alpha$  and PPAR $\gamma$  Activators--. A copy of the filing receipt is attached to this request.

Applicants therefore request the issuance of a corrected filing receipt with the correct title.

Applicants submit that the error was the fault of the USPTO.

Respectfully submitted,

Date: February 4, 2004

  
Rosemarie R. Wilk-Orescan, Reg. No. 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

Pwai/1msm

MAR 08 2002

(61)



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/076,575	02/08/2002	1624	740	5698.220- US		10	1

CONFIRMATION NO. 2403

## FILING RECEIPT



\*OC000000007605429\*

Reza Green, Esq.  
Novo Nordisk of North America, Inc.  
Suite 6400  
405 Lexington Avenue  
New York, NY 10174-6401



Date Mailed: 03/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Lone Jeppesen, Virum, DENMARK;  
Paul Stanley Bury, Kobenhavn, DENMARK;  
Per Sauerberg, Farum, DENMARK;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/419,761 10/19/1999  
AND CLAIMS BENEFIT OF 60/105,912 10/28/1998

## Foreign Applications

DENMARK PA 1998 01352 10/21/1998

If Required, Foreign Filing License Granted 03/07/2002

Projected Publication Date: 06/20/2002

Non-Publication Request: No

Early Publication Request: No

## Title

Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma

RECEIVED

MAR 05 2004

TECH CENTER 1600/2900

Preliminary Class  
514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FILE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(c) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/076,575	02/08/2002	Lone Jeppesen	5698.220-US

Reza Green, Esq.  
Novo Nordisk of North America, Inc.  
100 College Rd. W.  
Princeton, NJ 08540-6604

RECEIVED

MAR 05 2004

TECH CENTER 1600/2900

CONFIRMATION NO. 2403



\*OC000000011965810\*

Date Mailed: 02/25/2004

RESPONSE TO REQUEST FOR CORRECTED FILING RECEIPT

Title of Invention

In response to your request for a corrected Filing Receipt, the Office cannot comply with your request because:

- ☐ The articles such as "a", "an", and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- ☐ The words "new", "improved", "improvement of", "improvement in", or "improvement relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement. See MPEP 606.
- ☐ The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- ☐ Superscript and subscript are not possible. These characters will appear on the same line.
- ☐ The title appears on the filing receipt in sentence case for publication in the Annual Index of Patents.
- ☐ The title of the invention was captured as provided by applicant on the first page of the specification. An amendment is needed to make this change. (See MPEP 605.02.)
- ☒ The symbol that you have requested as part of the title cannot be captured as presented. It has been captured as written text.

ML. Steadman  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202